Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Click Therapeutics

PharmaDeviceNews Click Therapeutics

Representative image Smartphone-based digital therapy illustrates FDA-cleared Motivista from Click Therapeutics for treating negative symptoms of schizophrenia alongside standard care.

Pharma & Biotech

FDA clears digital therapeutic Motivista after positive Phase III schizophrenia trial

by Soujanya Ravi
October 5, 2026
0 Comments

FDA clears Click Therapeutics’ Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia.

Read More

Latest news and features

Rhapsido doubles complete hive response rate as Novartis secures new FDA indication
Solengepras delivers positive ARISE Phase 3 results as Cerevance prepares for FDA talks
Oral infigratinib moves toward FDA decision after positive PROPEL 3 trial
Firmonertinib misses pivotal endpoint as investigator and independent PFS results diverge
FDA clears digital therapeutic Motivista after positive Phase III schizophrenia trial
BBP-418 Phase 3 analysis adds cardiac signal to positive LGMD2I/R9 efficacy package
Abbott’s CardioMEMS app approval brings heart pressure data directly to patients
Roche cuts MS relapses up to 58.5% with fenebrutinib as FDA weighs an oral rival to its own Ocrevus
NewAmsterdam Pharma and Menarini win EU approval for Ubeslo and Evlarco
AMT-130 four-year data extend Huntington’s disease signal as FDA evaluates uniQure BLA
Novo Nordisk bets up to $2.6bn on Hengrui’s once-weekly oral GLP-1/GIP drug
Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

21 children, dozens of cameras and a California mansion: Inside the surrogacy case prosecutors call unprecedented
Parabolic Q3 revenue jumps 106% as ConnectAndSell acquisition transforms growth profile
US resident charged over alleged role in deadly Canada school shooting
TOP Ships acquires four ice-class tankers as potential revenue backlog reaches $1.24bn
Beam Global to acquire ScoutDI for $24m as it targets U.S. defense drone market

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.